艾德威斯治疗公司的sevasemten在减少贝克尔肌肉发育不良患者的肌肉损伤方面显示出有前途. Edgewise Therapeutics' sevasemten shows promise in reducing muscle damage in Becker muscular dystrophy patients.

艾德威斯治疗公司报告了其对贝克尔肌肉缩的Sevasemten第二期试验的积极结果. Edgewise Therapeutics reported positive results from its Phase 2 trial of sevasemten for Becker muscular dystrophy. 与安慰剂相比,该药物降低了肌肉损伤标志物肌酸酶水平28%. The drug reduced creatine kinase levels, a marker for muscle damage, by 28% compared to placebo. 虽然病人流动评估呈改善趋势,但没有观察到重大变化。 While there was a trend toward improvement in patients' ambulatory assessments, no significant changes were observed. 治疗期良好,没有新的安全关切。 The treatment was well-tolerated with no new safety concerns.